TransMedics Group, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. The company is a commercial-stage medical technology business focused on its Organ Care System (OCS), a platform for preserving and managing donor organs for transplant. This unaudited report covers the three months ended March 31, 2022; comparisons are with Q1 2021 unless otherwise stated. The company operates as one reportable segment.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Net revenue | $15.9 million | $7.1 million |
| Gross profit / gross margin | $12.1 million / 76% | $4.8 million / 68% |
| Operating expenses | $21.5 million | $11.3 million |
| Operating loss | $9.4 million | $6.5 million |
| Net loss | $10.6 million; $0.38 per share | $7.9 million; $0.29 per share |
| Cash used in operating activities | $18.4 million | $7.3 million |
| Cash and cash equivalents | $17.9 million at March 31, 2022 | $25.6 million at December 31, 2021 |
| Marketable securities | $54.1 million at March 31, 2022 | $66.9 million at December 31, 2021 |
| Debt | $35.3 million carrying value; $35.0 million principal | $35.2 million carrying value at December 31, 2021 |
Cash, cash equivalents and marketable securities totaled $72.0 million at quarter-end. Current assets were $105.8 million and current liabilities were $20.3 million. The company reported an accumulated deficit of $453.0 million and expects to continue operating at a loss. No dividend or profitability guidance is provided.
Material changes versus Q1 2021
- Revenue rose $8.8 million, approximately 125%. OCS Liver revenue increased to $7.9 million from $0.4 million and OCS Heart revenue rose to $5.7 million from $4.2 million; OCS Lung revenue declined to $2.3 million from $2.4 million.
- U.S. revenue increased to $13.6 million from $5.8 million, primarily reflecting OCS Liver and Heart commercial sales following FDA approvals in September 2021. International revenue increased to $2.3 million from $1.3 million.
- Gross margin improved to 76% from 68%, which management attributed primarily to higher volume, economies of scale and increased pricing.
- Operating expenses increased $10.2 million, including a $7.2 million increase in selling, general and administrative expenses as the company expanded its team and National OCS Program, and a $3.0 million increase in research, development and clinical trial expenses.
- Net loss widened by $2.6 million. Operating cash use increased by $11.1 million, reflecting the larger loss and working-capital needs, including higher receivables and inventory and lower accounts payable.
Outlook, risks and notable items
- Management believes available cash, cash equivalents and marketable securities can fund operations, capital expenditures and debt service for at least 12 months after filing. It cautions that estimates depend on assumptions and additional funding may be needed; financing may not be available on acceptable terms.
- The $35.0 million OrbiMed credit facility matures in June 2023, with principal and accrued interest due at maturity. It requires interest-only quarterly payments, carries a 9.5% stated rate at March 31, 2022, and has an approximately 11.2% weighted-average effective rate for the quarter. The company reported covenant compliance; the facility includes a $3.0 million minimum-liquidity covenant and substantial asset security.
- Management expects long-term increases in commercial, manufacturing, research and regulatory spending. It expects gross margin to improve over the long term with scale, while cautioning that margins may fluctuate by quarter. No quantified revenue or earnings guidance is presented.
- COVID-19 and its variants may disrupt transplant procedures, supply chains, staffing, clinical trials and regulatory review. Inflation, trade measures and shipping costs may also affect input costs and availability. Certain components are obtained from sole, single or limited-source suppliers.
- Revenue and receivables are concentrated: three customers each represented at least 10% of Q1 revenue; four customers represented at least 10% of receivables at quarter-end. The filing also cites dependence on OCS adoption, reimbursement, regulatory approvals, competition and potential need for further capital.
- On April 28, 2022, after quarter-end, the company received FDA premarket approval for OCS Heart use with donation-after-circulatory-death organs. The filing reports no material legal proceedings. An $8.0 million non-cancellable purchase commitment remained at March 31, 2022, under a contract extending through 2029.
Important facts for investors to verify
- Whether revenue growth—especially OCS Liver and Heart sales—continues, and whether OCS Lung volumes recover from the Omicron-related decline.
- Whether improved gross margin is sustained as volumes grow and product mix, pricing and manufacturing costs change.
- Cash burn, working-capital requirements and the company’s stated funding runway, including the timing and terms of any additional financing.
- Plans and ability to repay or refinance the OrbiMed facility at its June 2023 maturity, and continued compliance with its covenants.
- Commercial uptake, reimbursement and clinical or regulatory progress following the OCS Heart DCD approval, alongside customer and supplier concentration risks.